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ogy and signiﬁcant investment in developing anticancer therapeutics,
the mortality rates for many common cancers have not improved or
have improved only slightly in the past two decades. Innovative
approaches are needed to improve the efﬁcacy and the therapeutic
index of anticancer therapy. Nanomedicines based on nanometer-
sized materials that carry therapeutic agents may hold the potential to
improve tumor control and reduce treatment side effects by improving
the pharmacokinetics and tumor deposition of the drug payloads (Davis
et al., 2008). In animalmodels,monotherapy nanomedicines successful-
ly take advantage of prolonged blood circulation times to efﬁciently
deliver therapeutic agents to tumors via the enhanced permeability
and retention (EPR) effect. Nanomedicines have been modiﬁed with
active targeting ligand and/or endowed with controlled release proper-
ties to further enhance tumor selectivity and drug deposition in cancer
cells which in turn enhances efﬁcacy and reduces toxicity (Davis et al.,
2008). Clinically, however, nanomedicine formulations have largely
failed to meaningfully improve the efﬁcacy of chemotherapeutic
interventions, in spite of their reduced toxicity. The two FDA-
approved liposomal doxorubicin formulations Doxil® (PEGylated
liposomal doxorubicin) and Myocet® (non-PEGylated liposomal
doxorubicin) reduce most side effects (i.e. cardiomyopathy, bone
marrow depression, alopecia and nausea) while increasing a few
(palmar-plantar erythrodysesthesia and dermatologic toxicity). How-
ever, the formulations do not enhance anti-tumor effects in metastatic
breast cancer, multiple myeloma, or Kaposi's sarcoma. Myocet®
reduced the incidence of cardiac events and congestive heart failure,
but showed no improvements in response rate or progression-free
survival when compared to free doxorubicin in a Phase III trial in meta-
static breast cancer patients. CRLX101, a polymeric micelle carrying
camptothecin, was highly efﬁcacious in animal studies but did not
provide overall survival beneﬁt when compared to best supportive
care in a Phase 2b trial enrolling previously treated non-small cell lung
cancer (NSCLC) patients (NCT01380769). There are several other
examples ofmonotherapy nanomedicines that fail to produce enhanced
response rates over conventional chemotherapy in clinical trials despite
promising preclinical efﬁcacy results in animal models.⁎ Corresponding author.
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and clinical human trial data are debated in the nanomedicine commu-
nity, but we believe that the primary reasons are the less pronounced
EPR effect in and the heterogeneity of human tumors as well as the in-
trinsic or acquired resistance to monotherapy. The less pronounced
EPR effect in human tumors calls for nanomedicines with even superior
pharmacokinetics and tumor deposition which are being actively
pursued by researchers. Combination therapy can theoretically have
an increased chance of addressing the issues of tumor heterogeneity
and drug resistance. Cancers involve multiple pathways and often
develop different successive mutations and intrinsic or acquired
resistance as they progress (Gottesman, 2002). In conventional mono-
chemotherapy, it was long established that patients became less sensi-
tive over the treatment courses as their cancers acquired resistance to
the drug. Administration of multiple chemotherapeutics in a combina-
tion therapy has become a standard practice in conventional chemo-
therapy in order to take advantage of distinct mechanisms of action to
overcome cross-resistance and achieve synergistically enhanced
therapeutic outcome without signiﬁcantly increasing toxicities. It is
thus no surprise that recent clinical trials of nanomedicines have
focused on evaluating the therapeutic efﬁcacy of combination therapies.
Several ongoing clinical trials are evaluating the feasibility of com-
bining chemotherapeutic nanomedicines with radiotherapy or small
molecule drugs (such as gemcitabine). Pegylated liposomal doxorubicin
has shown improved therapeutic efﬁcacy when combined with radio-
therapy in several animal studies and clinical trials. A Phase I trial of
poly(L-glutamic acid)-bound paclitaxel (Xyotax) and fractionated
radiotherapy reported four complete and seven partial responses
(with reductions in tumor volume of N50%) in 12 patients with
advanced esophageal and gastric cancers (Dipetrillo et al., 2006). An
ongoing Phase 1b/2 investigator-initiated trial of CRLX101 combines
CRLX101, capecitabine, and radiotherapy for treating patients with
non-metastatic rectal cancer (NCT02010567). NC-6004, a polymeric
nanoformulation carrying cisplatin, showed reduced ototoxicity and
neurotoxicity while appearing to maintain therapeutic efﬁcacy in com-
bination with gemcitabine in Phase II clinical trials of pancreatic cancer
in the UK and Japan. In the clinical trial in Japan, 1 out of 19 patients had
a partial response, and 10 had stable disease. Themedian overall surviv-
al and PFS were 8.2 months and 3.8 months, respectively, which was
comparable to what is seen with the standard combination therapy
of nab-paclitaxel (Abraxane®) and gemcitabine. This combinationC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cally advanced and/or metastatic pancreatic cancer (NCT02043288)
and Phases I & II clinical trials for the treatment of advanced solid
tumors or NSCLC (NCT02240238) (Cabral and Kataoka, 2014).
To optimize combination therapy of cancers, next-generation
nanomedicines are developed to co-deliver multiple drugs or accom-
modate multiple therapeutic modalities. Combiningmultiple therapeu-
tic agents or modalities in a single platform offers the advantages of
vehicle uniformity, ratiometric drug loading, and spatiotemporal drug
release over single drug-containing particles. Langer and coworkers
developed nanomaterials composed of polymers and cationic lipids for
the co-delivery of cisplatin and siRNA ormicro RNAmimics and siRNAs,
which showed enhanced anticancer efﬁcacy over monotherapies
in mouse models of prostate cancer and lung cancer, respectively (Xue
et al., 2014; Xu et al., 2013).We recently reported a versatile nanoparti-
cle platform based on nanoscale coordination polymers (NCPs) that
enables different combination therapies and has demonstrated dramat-
ically enhanced anticancer efﬁcacy compared tomonotherapy nanopar-
ticles in mouse models with different types of resistant cancers (Liu
et al., 2014; He et al., 2015a, 2015b; Poon et al., 2015). We developed
NCP-1 carrying high payloads of cisplatin and the photosensitizer
pyrolipid for combined chemotherapy and photodynamic therapy
(PDT) (He et al., 2015a). NCP-1produced superior rates of tumor regres-
sion (83% reduction in tumor volume) to monotherapy nanoparticles
containing equal dose of cisplatin or pyrolipid alone in a subcutaneous
xenograft mouse model of radiotherapy and cisplatin-resistant head
and neck cancer. We also reported a variant of the NCP particle (NCP-
2) that carries oxaliplatin and gemcitabine monophosphate for the
synergistic combination therapy of pancreatic cancer (Poon et al.,
2015). To preemptively overcome drug resistance, we developed
NCP-3 carrying cisplatin and pooled siRNAs targeting drug-
resistant genes P-glycoprotein, Bcl-2, and survivin. Intratumoral
injection of NCP-3 led to tumor regression (~60% reduction in
tumor volume) in the cisplatin-resistant SKOV-3 ovarian cancer
subcutaneous xenograft mouse model over nanoparticles of cisplatin
or combination of free cisplatin and siRNAs (He et al., 2015b).
Recent clinical and preclinical data demonstrate the potential of
nanomedicines in combination therapy of cancers using multiple
therapeutic agents ormodalities. In the next few years, signiﬁcant effort
should be invested in establishing novel and optimal combination
regimens, such as the combination of chemotherapy with siRNA
in order to achieve improved therapeutic outcomes. Combinationnanomedicines can be further modiﬁed with antibody or other tumor-
targetingmolecules to increase tumor deposition. An ideal combination
nanomedicine is anticipated to achieve synergistically enhanced
therapeutic outcome but no additive toxicity and, equally importantly,
to rely on simple, straightforward, and scalable manufacturing process-
es with minimal batch-to-batch variations. Next-generation combina-
tion nanomedicines are expected to reduce toxicity, enhance efﬁcacy,
and overcome drug resistance to elicit sustained treatment responses
in cancer patients.Acknowledgment
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